However, the 18 FMCs with a 2+ score by HER2 immunohistochemistry were not evaluated by dual-probe in situ hybridization, as recommended for breast cancers (35), so HER2-positive FMCs were underestimated in the present study. This evidence concerns the gene ERBB2 and breast carcinoma.